Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.17
CHRS's Cash-to-Debt is ranked lower than
78% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CHRS: 1.17 )
Ranked among companies with meaningful Cash-to-Debt only.
CHRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.17  Med: 44.6 Max: No Debt
Current: 1.17
Equity-to-Asset 0.19
CHRS's Equity-to-Asset is ranked lower than
89% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CHRS: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
CHRS' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.05  Med: 0.16 Max: 0.39
Current: 0.19
-2.05
0.39
Debt-to-Equity 3.14
CHRS's Debt-to-Equity is ranked lower than
96% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CHRS: 3.14 )
Ranked among companies with meaningful Debt-to-Equity only.
CHRS' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.64  Med: 0.62 Max: 4.93
Current: 3.14
-1.64
4.93
Debt-to-EBITDA -0.92
CHRS's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CHRS: -0.92 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CHRS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.92  Med: -0.09 Max: -0.02
Current: -0.92
-0.92
-0.02
Piotroski F-Score: 3
Altman Z-Score: -2.41
Beneish M-Score: 3.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -71.35
CHRS's Operating Margin % is ranked higher than
54% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CHRS: -71.35 )
Ranked among companies with meaningful Operating Margin % only.
CHRS' s Operating Margin % Range Over the Past 10 Years
Min: -2028.33  Med: -729.23 Max: -60.98
Current: -71.35
-2028.33
-60.98
Net Margin % -73.89
CHRS's Net Margin % is ranked higher than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CHRS: -73.89 )
Ranked among companies with meaningful Net Margin % only.
CHRS' s Net Margin % Range Over the Past 10 Years
Min: -1949.65  Med: -743.18 Max: -66.98
Current: -73.89
-1949.65
-66.98
ROE % -593.73
CHRS's ROE % is ranked lower than
97% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CHRS: -593.73 )
Ranked among companies with meaningful ROE % only.
CHRS' s ROE % Range Over the Past 10 Years
Min: -1778.45  Med: -1257.68 Max: -593.73
Current: -593.73
-1778.45
-593.73
ROA % -59.75
CHRS's ROA % is ranked lower than
69% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CHRS: -59.75 )
Ranked among companies with meaningful ROA % only.
CHRS' s ROA % Range Over the Past 10 Years
Min: -145  Med: -111.74 Max: -59.75
Current: -59.75
-145
-59.75
ROC (Joel Greenblatt) % -927.87
CHRS's ROC (Joel Greenblatt) % is ranked lower than
60% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CHRS: -927.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CHRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2990.18  Med: -2679.87 Max: -927.87
Current: -927.87
-2990.18
-927.87
3-Year Revenue Growth Rate 189.50
CHRS's 3-Year Revenue Growth Rate is ranked higher than
98% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CHRS: 189.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CHRS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 94.75 Max: 189.5
Current: 189.5
0
189.5
3-Year EBITDA Growth Rate -5.10
CHRS's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CHRS: -5.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CHRS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.55 Max: -5.1
Current: -5.1
3-Year EPS without NRI Growth Rate 2.80
CHRS's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CHRS: 2.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CHRS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.4 Max: 2.8
Current: 2.8
0
2.8
GuruFocus has detected 3 Warning Signs with Coherus BioSciences Inc CHRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CHRS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CHRS Guru Trades in Q3 2016

Joel Greenblatt 17,363 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 10,670 sh (-5.58%)
» More
Q4 2016

CHRS Guru Trades in Q4 2016

Steven Cohen 601,034 sh (New)
Joel Greenblatt 32,982 sh (+89.96%)
Paul Tudor Jones 14,396 sh (+34.92%)
» More
Q1 2017

CHRS Guru Trades in Q1 2017

Jim Simons 113,200 sh (New)
Paul Tudor Jones 23,223 sh (+61.32%)
Joel Greenblatt 36,380 sh (+10.30%)
Steven Cohen Sold Out
» More
Q2 2017

CHRS Guru Trades in Q2 2017

Paul Tudor Jones 28,681 sh (+23.50%)
Joel Greenblatt Sold Out
Jim Simons 21,900 sh (-80.65%)
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Sold Out 0.01%$14.45 - $24.5 $ 13.70-29%0
Joel Greenblatt 2017-03-31 Add 10.30%$20.5 - $29.05 $ 13.70-44%36,380
Joel Greenblatt 2016-12-31 Add 89.96%$24.15 - $30.69 $ 13.70-51%32,982
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2836
Compare:NAS:CRSP, HKSE:01681, NAS:MCRB, NAS:RXDX, NAS:AMAG, NAS:ACRS, NAS:PRTK, XPAR:IPH, SZSE:300181, NAS:MGNX, NAS:CTMX, NAS:INSY, NAS:AKAO, SZSE:002286, NAS:GTHX, NAS:WVE, NAS:PTCT, NAS:ITCI, HKSE:06826, SHSE:603896 » details
Headquarter Location:USA
Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.

Coherus BioSciences is a biotechnology company that develops biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia, and Latin America. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines. Coherus generates the vast majority of its revenue in the United States.

Top Ranked Articles about Coherus BioSciences Inc

Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
Coherus Secures Private Placement from Temasek
Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results
Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522
Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th
Covered Call reports for Amazon.com, Coherus Biosciences, 3D Systems, The Kroger Co and Tesla Motors include trade ideas that offer returns of 24% or more!
Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
9 Stocks Joel Greenblatt Continues to Buy The guru added to these holdings in the past 2 quarters
Joel Greenblatt (Trades, Portfolio) is founder and managing partner of Gotham Asset Management LLC . In both first-quarter 2017 and fourth-quarter 2016 the guru bought shares in the following stocks: Read more...

Ratios

vs
industry
vs
history
PB Ratio 21.88
CHRS's PB Ratio is ranked lower than
93% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CHRS: 21.88 )
Ranked among companies with meaningful PB Ratio only.
CHRS' s PB Ratio Range Over the Past 10 Years
Min: 6.35  Med: 21.75 Max: 63.17
Current: 21.88
6.35
63.17
PS Ratio 4.27
CHRS's PS Ratio is ranked higher than
74% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CHRS: 4.27 )
Ranked among companies with meaningful PS Ratio only.
CHRS' s PS Ratio Range Over the Past 10 Years
Min: 3.46  Med: 16.91 Max: 41.41
Current: 4.27
3.46
41.41
EV-to-EBIT -6.87
CHRS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CHRS: -6.87 )
Ranked among companies with meaningful EV-to-EBIT only.
CHRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.6  Med: -6.3 Max: -1.6
Current: -6.87
-15.6
-1.6
EV-to-EBITDA -7.07
CHRS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CHRS: -7.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
CHRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16  Med: -6.3 Max: -1.6
Current: -7.07
-16
-1.6
EV-to-Revenue 4.69
CHRS's EV-to-Revenue is ranked higher than
75% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CHRS: 4.69 )
Ranked among companies with meaningful EV-to-Revenue only.
CHRS' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.3  Med: 13.8 Max: 38.7
Current: 4.69
3.3
38.7
Current Ratio 4.27
CHRS's Current Ratio is ranked higher than
51% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CHRS: 4.27 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.67 Max: 4.4
Current: 4.27
0.85
4.4
Quick Ratio 4.27
CHRS's Quick Ratio is ranked higher than
54% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CHRS: 4.27 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.67 Max: 4.4
Current: 4.27
0.85
4.4
Days Sales Outstanding 0.06
CHRS's Days Sales Outstanding is ranked higher than
100% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CHRS: 0.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.06  Med: 28.36 Max: 36.88
Current: 0.06
0.06
36.88

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -46.10
CHRS's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CHRS: -46.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CHRS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -46.1  Med: -23.05 Max: 0
Current: -46.1
-46.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 52.69
CHRS's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CHRS: 52.69 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CHRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.22  Med: 31.9 Max: 351.88
Current: 52.69
9.22
351.88
Price-to-Tangible-Book 24.60
CHRS's Price-to-Tangible-Book is ranked lower than
90% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CHRS: 24.60 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CHRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 8.58  Med: 23.39 Max: 76.08
Current: 24.6
8.58
76.08
Price-to-Median-PS-Value 0.25
CHRS's Price-to-Median-PS-Value is ranked higher than
91% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CHRS: 0.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CHRS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 0.89 Max: 1.66
Current: 0.25
0.25
1.66
Earnings Yield (Greenblatt) % -14.56
CHRS's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CHRS: -14.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CHRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -62  Med: -15.9 Max: -6.4
Current: -14.56
-62
-6.4

More Statistics

Revenue (TTM) (Mil) $165.24
EPS (TTM) $ -2.74
Short Percentage of Float16.48%
52-Week Range $10.80 - 31.48
Shares Outstanding (Mil)57.92

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 33 127 262
EPS ($) -3.46 -2.54 -0.82 0.95
EPS without NRI ($) -3.46 -2.54 -0.82 0.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}